An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study is testing a new medication called Luspatercept. It's for people in the UK who have a blood condition called myelofibrosis, which causes anaemia (low red blood cells), and who need regular blood transfusions. Participants must already be taking a JAK2 inhibitor medicine for their myelofibrosis. The main goal is to find out if Luspatercept is safe and effective at reducing how often people need blood transfusions. Some people will receive Luspatercept, while others will get a placebo (a dummy drug). This helps doctors understand if the new drug truly works. Participants will be carefully monitored throughout the study.
A colpo d'occhio
Risultati
Risultati di questo studio
Pubblicato July 2026I risultati di questo studio sono stati pubblicati.
Di cosa tratta questo studio?
This research study is about a condition called myelofibrosis. Myelofibrosis is a rare type of blood cancer where the bone marrow, which makes blood cells, becomes scarred and doesn't work properly. This often leads to severe anaemia, meaning your body doesn't have enough red blood cells to carry oxygen, making you feel tired and weak. Many people with myelofibrosis need regular blood transfusions.
Doctors are testing a new drug called Luspatercept (you might also see it called ACE-536). It's designed to help your body make more healthy red blood cells. The study wants to see if Luspatercept can help people with myelofibrosis reduce the number of blood transfusions they need, and if it's generally safe to use. You would be eligible if you're already taking a specific type of medication called a JAK2 inhibitor for your myelofibrosis.
In this study, some people will receive Luspatercept, and others will get a placebo, which looks like the study drug but contains no active medicine. This is a common way to test new drugs reliably. At first, neither you nor your doctor will know if you're getting the active drug or the placebo. After about six months, if you haven't seen a benefit, you'll have the option to find out what you were taking. If you were on the placebo, you might then be able to start taking Luspatercept.
Punti chiave
- This study tests a new drug, Luspatercept, for myelofibrosis with anaemia.
- It aims to reduce the need for blood transfusions.
- Participants must already be taking a JAK2 inhibitor.
- Some will receive the drug, others a placebo (dummy drug).
- Close medical monitoring will be provided throughout.
- Puoi smettere di partecipare in qualsiasi momento.
Chi può essere idoneo?
To join this study, you need to be at least 18 years old and have a confirmed diagnosis of myelofibrosis. Critically, you must be experiencing anaemia that requires regular red blood cell transfusions. This means you’ve had between 4 and 12 red blood cell units over the last 12 weeks, and you haven’t gone longer than six weeks without a transfusion.
You must also already be taking a JAK2 inhibitor medication for your myelofibrosis. This medication needs to have been stable (same dose, no interruptions) for a certain period before the study starts. Your general health should also be reasonably good, as assessed by a doctor, meaning you're able to carry out most daily activities.
There are also some types of other medications or therapies that you cannot be taking while in this study, such as certain cancer drugs (other than your JAK2 inhibitor), specific blood cell growth factors, or certain older medications for blood conditions. Your study doctor will review all your current medications carefully to make sure you can safely participate.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Do you have myelofibrosis and need regular blood transfusions (at least 4 units in the last 12 weeks)?
- Are you currently taking a JAK2 inhibitor medication for your myelofibrosis?
- Has your JAK2 inhibitor dose been stable for at least 16 weeks?
- Are you generally well enough to do most daily activities?
Cosa comporta la partecipazione?
If you decide to take part, the study will involve several stages. First, there's a 'screening period' where doctors will check if you meet all the requirements. If you do, you'll enter the 'treatment phase'. This phase starts with a period where you'll receive either Luspatercept or a placebo, and neither you nor your doctors will know which one. This part lasts for around six months. During this time, you will continue your usual JAK2 inhibitor treatment and other supportive care, like blood transfusions if needed.
Around day 169 (about 5.5 months), your response to the treatment will be checked. If you haven't shown improvement, you'll have the option to find out if you were on the active drug or placebo. If you were on the placebo, you might then be able to receive Luspatercept. The study involves regular clinic visits for assessments, blood tests, and to get your study medication. You'll then have a follow-up period after your treatment ends. The total duration of your involvement could be quite long, potentially over a year, depending on which treatment arm you are in and if you continue into the extension periods.
Rischi e benefici potenziali
Locations (185)
- Local Institution - 110Codice postale verificatoLos Angeles, Stati Uniti
- Local Institution - 135Codice postale verificatoOrlando, Stati Uniti
- Local Institution - 133Codice postale verificatoPlantation, United States
- Local Institution - 112Codice postale verificatoChicago, Stati Uniti
- Local Institution - 124Codice postale verificatoLexington, Stati Uniti
- Local Institution - 114Codice postale verificatoAnn Arbor, Stati Uniti
- Local Institution - 108Codice postale verificatoSt Louis, Stati Uniti
- John Theurer Cancer CenterCodice postale verificatoHackensack, United States
- Centro Medico Monte SinaiCodice postale verificatoNew York, Stati Uniti
- University of Pittsburg Medical CenterCodice postale verificatoPittsburgh, United States
- Allegheny Health NetworkCodice postale verificatoPittsburgh, United States
- Local Institution - 130Codice postale verificatoKnoxville, United States
Domande comuni
What is myelofibrosis?
It's a rare blood cancer where your bone marrow becomes scarred, affecting its ability to make healthy blood cells, often leading to anaemia.
What is Luspatercept?
It's a new medication being tested to help your body produce more red blood cells, potentially reducing the need for blood transfusions.
Che cos'è un placebo?
A placebo is a 'dummy' treatment that looks like the study drug but contains no active medicine. It helps compare the new drug's effects.
Will I still take my JAK2 inhibitor?
Yes, you must continue your stable JAK2 inhibitor treatment throughout the study as part of your standard care.
Posso lasciare lo studio in qualsiasi momento?
Yes, you are free to withdraw from the study for any reason at any point, without it affecting your medical care.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.